Executive Summary

PT. Imsmart IMT Indonesia, under President Commissioner Madam Mandala Soottapintu, is leading a landmark investment in IKN as part of the DERMA-CURE KMWSH Consortium. Beyond the IDR 3 trillion Mandala Nusantara International Hospital, the alliance commits a one billion dollar portfolio including Precision Nutrition and Traditional Pharmaceutical Industry, Smart Office Towers, a Small Electric Airplane Factory for inter-island logistics, and patented Smart Building Technology. This integrated approach delivers world-class healthcare, solves archipelagic logistical challenges, and supports IKN development.

​

Project Overview and Strategic Alliance

The Mandala Nusantara International Hospital is the healthcare flagship of a broader investment strategy. PT. Imsmart IMT Indonesia, led by Madam Mandala Soottapintu, provides strategic oversight. The international consortium comprises DERMA-CURE FOR PHARMACEUTICAL INDUSTRIES, an Egyptian company represented by inventor Mr. Sherif Salah Abdelaziz Hesen specializing in nutrigenomics and traditional pharmaceuticals, and KMWSH ENDUSTRiYEL PROJE, a Turkish-registered company represented by inventor Mr. Muayad S. Dawood Al-Samaraee specializing in electric aircraft and smart building systems. Local facilitation is provided by LP2LI, the Indonesian Institute for Environmental Management and Restoration, represented by Mr. Troy Evelon Pomalingo. The project occupies five hectares in IKN, East Kalimantan, with total investment of one billion dollars.

​

The Expanded Investment Portfolio

The consortium builds an integrated ecosystem generating multiple revenue streams. The Mandala Nusantara International Hospital represents IDR 3 trillion as the flagship facility. The Precision Nutrition and Traditional Pharmaceutical Industry produces personalized nutrigenomic testing and traditional medicine formulations leveraging Indonesia's biodiversity. The global precision nutrition market is projected to grow from USD 6.33 billion in 2024 to USD 9.59 billion by 2030. The Small Electric Airplane Factory produces aircraft with two to eight passenger capacity and payloads of 100 to 1000 kilograms, addressing inter-island transport challenges. Office towers and commercial projects create a mixed-use business district generating rental income. All construction utilizes patented smart building technology.

​

Precision Nutrition and Traditional Pharmaceutical Industry

Indonesia's herbal medicine market is estimated at USD 1 to 2.7 billion annually, with exports exceeding USD 200 million. The consortium integrates nutrigenomics with traditional medicine, creating "precision jamu nutrition" that combines cultural acceptability with scientific validation. The nutrigenomic approach examines over 50 genes and 75 genetic variations to personalize dietary and supplement recommendations. DERMA-CURE develops standardized extracts of botanicals including Curcuma longa, Zingiber officinale, Andrographis paniculata, and Centella asiatica, all with demonstrated nutrigenomic effects on inflammatory, antioxidant, metabolic, and mitochondrial pathways. This integrated service provides culturally resonant, scientifically validated precision healthcare.

​

Revolutionary Smart Building Technology

The consortium's proprietary dry construction method produces zero waste, aligning with IKN's green city mandate. The material resists fires and earthquakes up to 9.8 Richter, ensuring safety. Implementation is rapid and significantly lower cost than traditional methods, enabling faster operational launch and quicker returns.

​

Market Analysis and Competitive Advantages

The Asia-Pacific precision nutrition market is expected to grow at 16.6% CAGR through 2032, driven by proactive policies and digital health infrastructure. Indonesia's Ministry of Health has endorsed the Precision Medicine Clinic at RSCM Kencana, including nutrigenomic testing, while RSU Royal Prima in Medan has launched similar services. The consortium's integration of traditional medicine with nutrigenomics uniquely positions it in a market where herbal medicine acceptance is high. The aviation component addresses Indonesia's 17,000-island logistical challenge through electric vertical takeoff and landing aircraft for high-value nutraceutical and medical supply transport. Within IKN, competitors include Mayapada Hospital Nusantara and government RSUP IKN. Mandala Nusantara's IDR 3 trillion investment, smart building cost advantages, and vertical pharmaceutical integration establish it as the premier facility.

​

Strategic Synergy with IKN Fiscal Incentives

Government Regulation Number 12 of 2023 provides 100% corporate income tax reduction for up to thirty years for infrastructure and public service investments. The healthcare sector qualifies. Investors with minimum IDR 10 billion investment are eligible. R&D deductions up to 350% of costs benefit nutrigenomic research, traditional medicine standardization, electric aviation, and smart building innovation. Non-collected VAT and customs duty exemptions on capital goods apply until 2045. Collaboration with Indonesian SOEs strengthens incentive eligibility.

​

Phased Operational Plan

• Phase One, spanning years one to two, focuses on foundation and manufacturing. Smart building technology constructs the electric airplane factory and precision nutrition base. The nutrigenomic laboratory is established and regulatory approvals secured. Local geneticists, nutritionists, and pharmaceutical scientists are recruited and trained.

• Phase Two, covering years two to four, concentrates on hospital and commercial construction. The five-hectare hospital is built using dry-construction methods and equipped with advanced technology. Precision nutrition services launch with full nutrigenomic testing and personalized formulations. Electric airplane production begins for medical evacuation and inter-island supply routes.

• Phase Three, spanning years four to six, focuses on integration and expansion. The hospital is fully integrated with its precision nutrition division, offering complete care pathways from genetic testing through personalized treatment. The hospital operates its own aircraft fleet. Commercial office towers open for lease to SOEs and multinational companies.

​

Organizational Structure

Madam Mandala Soottapintu serves as President Commissioner overseeing government relations and investor strategy. Mr. Sherif Salah Abdelaziz Hesen leads precision nutrition and pharmaceutical R&D, managing nutrigenomic testing, traditional medicine standardization, and personalized supplement production. Mr. Muayad S. Dawood Al-Samaraee leads aviation and engineering, managing aircraft manufacturing and smart building implementation. Mr. Troy Evelon Pomalingo manages local operations, environmental compliance, and workforce integration.

​

Conclusion

Mandala Nusantara International Hospital is the healthcare anchor of a high-tech multi-sector hub in IKN. By integrating precision nutrition with traditional Indonesian medicine, revolutionary green construction, and inter-island aviation logistics, the consortium addresses Indonesia's unique challenges while delivering world-class personalized healthcare. Under Madam Mandala Soottapintu's leadership, this one billion dollar investment promises strong returns while actively supporting Indonesia's new capital vision.